Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study

Tadeusz Robak,Huiqiang Huang,Jie Jin,Jun Zhu,Ting Liu,Olga S Samoilova,Halyna Pylypenko,Gregor Verhoef,Noppadol Siritanaratkul,Evgenii A Osmanov,Julia Alexeeva,Juliana Pereira,Jiri Mayer,Xiaonan Hong,Yoshiharu Maeda,Lixia Pei,Brendan Rooney,Helgi Van De Velde,Franco Cavalli

doi:10.1182/blood.v124.21.4412.4412

Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study

Tadeusz Robak, Huiqiang Huang + Show 17 more

Open Access

https://doi.org/10.1182/blood.v124.21.4412.4412

Copy DOI

Journal: Blood	Publication Date: Dec 6, 2014
Citations: 2

Affiliation: Medical University of Lodz, Sun Yat-sen University Cancer Center, First Affiliated Hospital Zhejiang University, Peking University, Peking University Cancer Hospital, West China Hospital of Sichuan University, Nizhny Novgorod Regional Clinical Hospital named after Semashko, Universitair Ziekenhuis Leuven, Siriraj Hospital, Russian Cancer Research Center NN Blokhin, Federal State Budgetary Institution "Federal Center For Cardiovascular Surgery" Ministry of Health of The Russian Federation, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Fudan University Shanghai Cancer Center, Tokyo Metropolitan Komagome Hospital, Janssen (United States), Janssen (United Kingdom), Janssen (Belgium), Ospedale San Giovanni Bellinzona

#Research Funding #Independent Radiology Review Committee + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.